Reticlear Announces New Retina Clearing Formula Using the Eye Flow Ritual Hack
Natural Vision Support Supplement Now Highlights Daily Retina Health Routine Known as the Eye Flow Ritual Hack
ENGLEWOOD, June 09, 2025 (GLOBE NEWSWIRE) --
Reticlear, a wellness-focused supplement brand based in Colorado, has announced updates to its official website featuring a natural formula designed to support retinal health and visual clarity. Marketed as a daily-use supplement, the product introduces a wellness concept referred to as the 'Eye Flow Ritual Hack,' now accessible to adults across the United States.
According to the official product site (https://reticlear.com), Reticlear is formulated to work in harmony with the body's internal systems to promote retinal cleansing, eye circulation, and visual function. The company presents the supplement as an easy-to-integrate solution for individuals seeking a natural approach to vision support without the need for complex regimens or restrictive routines.
'Our goal was to create a simple, routine-friendly formula to support long-term visual wellness,' said a company spokesperson. 'The Eye Flow Ritual Hack reflects our philosophy of blending nature-inspired practices with modern supplement science.'
Reticlear is produced in facilities that follow strict quality control and safety standards. The formulation includes plant-based ingredients selected to align with adult wellness goals related to ocular health and natural detox pathways. While individual results may vary, the product is intended for daily use as part of a proactive health routine.
As stated on the product's official website, Reticlear includes a satisfaction guarantee for new customers. Visitors can find ingredient insights, common usage questions, and direct purchasing options by visiting https://reticlear.com.
About Reticlear
Reticlear is a Colorado-based wellness brand committed to providing natural, easy-to-use supplements designed for daily health support. With a focus on transparency, simplicity, and user-centered formulations, Reticlear aims to help adults integrate wellness into their everyday lives.
Product and Contact Information
Brand: ReticlearWebsite: https://reticlear.comEmail: support@a1health.comPhone: +1 (580) 448-1129Mailing Address: 3365 James E Casey Ave, Englewood, CO 80112, USAReturn Address: 19655 E. 35th Dr. #100, Aurora, CO 80011
Disclaimer
This release is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. The statements made about this product have not been evaluated by the Food and Drug Administration. Individual results may vary. Consumers should consult a qualified healthcare provider before beginning any new dietary supplement.
CONTACT: Email: support@a1health.com Phone: +1 (580) 448-1129 Return Address: 19655 E. 35th Dr. #100, Aurora, CO 80011
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
15 minutes ago
- CBS News
Major expansion at veterinary hospital in Colorado's high country helps fill a gap in emergency pet care
Silverthorne Veterinary Hospital has reopened with eight times the space it once had, in part, as an effort to fill a gap in pet support often seen in Colorado mountain communities. CBS "It allows us to expand not only the amount of surgical procedures that we can do in a single day, the amount of patients that we can see in a single day, but it also allows us to expand our emergency services," owner and veterinarian Justin Milizio said. "Our first hospital just had ground floor, just hospital stuff. It was 1,000 square feet. ... This is 8,200 square feet. That's not to mention the an additional 4,500 square feet upstairs. Milizio said that's designed for built-in employee housing, with eight bedrooms total split between three apartments. Staying fully staffed will help them reach their eventual goal: 24/7 pet emergency medical response. "This hospital is really designed to expand hours and expand the capability, the machinery, the equipment, the staff that's needed to house animals so people don't have to go all the way down to Denver as much for emergency situations," Milizio said. CBS Summit County Resident Susan Burkey says she's counted on Silverthorne Veterinary Hospital with several of her dogs she trains over the years, and while she's had to make the trip to other veterinary hospitals in the past, she's hopeful this bigger version of SVH will limit those trips in the future. "It would be really great because then you don't have to go into Denver, Vail or anywhere else." CBS She said she's also eager for expanded hours. "You can come on the evenings, weekends and I know they're, you know, eventually, hopefully going to do 24/7 care." "All these emergency situations and some of them aren't necessarily too critical of emergencies, have always just been shunted down to Denver," Milizio said. "Sometimes the weather's bad and you can't make it down to Denver. Sometimes your car breaks down and you can't make it down to Denver. It is definitely a challenging part of pet ownership in this county, in this community."
Yahoo
30 minutes ago
- Yahoo
UnitedHealth Group received multiple bids for Latin American operations
-- UnitedHealth Group (NYSE:UNH) is considering several offers for its Latin American operations, according to a Reuters report on Monday. The move comes as the largest U.S. health insurer faces challenges that include the departure of its CEO and an alleged criminal accounting investigation. The insurer has been attempting to leave Latin America since 2022, with the sale of its Banmedica subsidiary becoming more urgent in recent months due to increasing pressures on multiple fronts, the report said. So far, UnitedHealth has reportedly received four preliminary bids for Banmedica, which operates in Colombia and Chile, with an estimated value of about $1 billion. In May, UnitedHealth's shares dropped 25.5%, and the year-to-date decline stands at 40%. The company withdrew from Brazil in 2023 and from Peru in March 2025. It aims to secure around $1 billion for Banmedica's operations in Colombia and Chile. The company anticipates setting a deadline for final proposals as early as July. The bids reportedly include offers from Washington, D.C.-based private equity firm Acon Investments, Sao Paulo-based private equity firm Patria Investments, Texas non-profit health organization Christus Health, and Lima-based healthcare and insurance provider Auna. The report mentioned that Auna is currently in discussions with a financial partner. Related articles UnitedHealth Group received multiple bids for Latin American operations Tesla shares slip after double downgrade amid Trump feud fallout What are the three big things in markets now? RBC weighs in
Yahoo
35 minutes ago
- Yahoo
RenaissThera Achieves Discovery Milestone in Its Oral Obesity Drug Program
BENGALURU, India, June 09, 2025 (GLOBE NEWSWIRE) -- RenaissThera Private Limited ('RenaissThera'), a Bengaluru-based biotechnology company, announced a major milestone in its obesity drug discovery program targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR). GIPR, an incretin receptor, is a validated target for peptide-based parenteral therapies where both stimulation and inhibition has shown efficacy in treating obesity and its co-morbidities. RenaissThera is developing novel, oral small molecules, both agonists and antagonists, as a more affordable and convenient alternative aiming to expand access for underserved populations in the global obesity market projected to reach USD 38 billion by 2032. Oral small molecules are more economical to manufacture and distribute than peptide-based obesity drugs. These molecules were designed and screened using proprietary AI and ML based platforms, followed by demonstrating in-vitro activity in cell lines and in-vivo activity to impact GIPR in mice to yield 'Hits'. RenaissThera now is advancing these Hits to the Lead optimization program to select candidates for pre-IND studies. RenaissThera is filing 'Composition of Matter' and utility patents for these oral novel small molecule GIPR modulators and continues to expand its innovation portfolio targeting GIP, GLP-1, and apelin receptors in obesity and diabetes. Its AI-powered Innovation Platform, integrating GenAI and machine learning tools, is accelerating the design and optimization of novel small molecules. 'We are grateful to our investors and collaborators for supporting us in reaching this milestone. Our team is focused on pushing candidates toward IND-readiness next year and we are in active discussions with potential pharma partners and investors interested in our obesity program,' said Meena, MD, CEO of RenaissThera. RenaissThera's progress was enabled through its collaboration with VedTechBio Research Private Limited which enabled access to its Agentic AI platform RxAgentAI and discovery expertise. 'We are very pleased with the outcomes of our collaboration with RenaissThera. This milestone further validates our platform and capabilities across key therapeutic areas including obesity, Type 2 diabetes, oncology, and inflammation,' said VedTechBio's Managing Director Sudhir Nagarajan. About RenaissThera RenaissThera is a Bengaluru-based biotech company developing affordable, AI-powered novel small-molecule therapies for high-unmet-need diseases like obesity and diabetes. Its goal is to innovate for underserved populations and expand global access to novel therapies. It leverages India's CRO ecosystem for early-stage R&D to deliver globally relevant innovation. For more information Please contact: Media: Lakshmi Ramakrishna lramakrishna@ Investor & Partnership: Ramkesh Meena bd@
